Linked e-resources
Details
Table of Contents
Preface; Acknowledgments; Contents; List of Contributors; 1: Radiological Imaging in Urological Cancers; 1.1 Introduction; 1.2 Renal Cancer; 1.2.1 General Information; 1.2.2 Imaging Techniques; 1.2.2.1 Ultrasonography; 1.2.2.2 Computed Tomography; 1.2.2.3 Magnetic Resonance Imaging; Malignant Tumors of Renal Pelvis; Metastases; Lymphoma; Primary Renal Mesenchymal Tumors; 1.2.3 Staging of Renal Tumors; 1.2.4 Intervention in Renal Masses; 1.3 Bladder Cancer; 1.3.1 General Information; 1.3.2 Imaging Features; 1.3.2.1 Ultrasonography; 1.3.2.2 Computed Tomography
1.3.2.3 Magnetic Resonance Imaging1.3.3 Staging; 1.3.3.1 Lymph Node Metastasis; 1.3.3.2 Metastasis Staging; 1.3.4 Monitoring After Treatment; 1.4 Prostate Cancer; 1.4.1 General Information; 1.4.2 Imaging Features; 1.4.2.1 Ultrasonography; 1.4.2.2 Computed Tomography; 1.4.2.3 Magnetic Resonance Imaging; 1.4.3 Local Staging of Patients with Biopsy-Proven Prostate Cancer; 1.4.3.1 Lymph Node Metastasis; 1.4.3.2 Distant Metastasis; 1.4.3.3 Preprocedural Assessment; 1.4.3.4 Metabolic Imaging; 1.4.3.5 Evaluation of Recurrence; References
2: Management of Non-muscle-Invasive and Muscle-Invasive Bladder Cancers2.1 Introduction; 2.2 Management of Non-muscle-Invasive Bladder Cancer; 2.3 Repeat/Restaging Transurethral Resection; 2.4 Intravesical Chemotherapy; 2.5 Intravesical Immunotherapy; 2.6 Treatment Alternatives During the Global Shortage of BCG; 2.6.1 Alternative BCG Schedules; 2.6.2 Alternative Intravesical Chemotherapy Applications; 2.7 Future Perspectives; 2.8 Treatment of Disease Unresponsive to or Relapsing After BCG Vaccination; 2.9 Upfront Cystectomy for Very High-Risk NMIBC
2.10 Surgical Management of Muscle-Invasive Bladder CancerReferences; 3: Target Volume Delineation Guidelines in Bladder Cancer; 3.1 Anatomy; 3.2 Role of Radiotherapy for Locoregional Disease; 3.3 Target Volume Delineation; 3.4 Definitive Radiotherapy for the Intact Bladder; 3.4.1 Gross Tumor Volume; 3.4.2 Clinical Target Volume; 3.4.3 Role of Elective Nodal Irradiation; 3.4.4 Planning Target Volume; 3.5 Adjuvant Setting; References; 4: Bladder Preservation Therapies in Bladder Cancer; 4.1 Introduction; 4.2 Management of Non-muscle-Invasive Bladder Cancer
4.3 Treatment of Muscle-Invasive Disease4.3.1 Monotherapy; 4.3.2 Multimodal Approach; 4.4 Metastatic Disease and Recurrences; 4.5 Irradiation Techniques; 4.5.1 Simulation, Target Volume, and Fields; 4.5.2 Tumor Localization; 4.5.3 Target Delineation; 4.5.4 Doses and RT Schedules; 4.5.5 IMRT and IGRT; 4.5.6 Brachytherapy; References; 5: Systemic Therapy for Bladder Cancer; 5.1 Introduction; 5.2 Systemic Therapies in Muscle-Invasive Bladder Cancer; 5.3 Treatment of Advanced and Metastatic Disease; 5.3.1 DNA-Targeted Chemotherapy; 5.3.2 Targeted Therapies; 5.3.3 Immunotherapy
1.3.2.3 Magnetic Resonance Imaging1.3.3 Staging; 1.3.3.1 Lymph Node Metastasis; 1.3.3.2 Metastasis Staging; 1.3.4 Monitoring After Treatment; 1.4 Prostate Cancer; 1.4.1 General Information; 1.4.2 Imaging Features; 1.4.2.1 Ultrasonography; 1.4.2.2 Computed Tomography; 1.4.2.3 Magnetic Resonance Imaging; 1.4.3 Local Staging of Patients with Biopsy-Proven Prostate Cancer; 1.4.3.1 Lymph Node Metastasis; 1.4.3.2 Distant Metastasis; 1.4.3.3 Preprocedural Assessment; 1.4.3.4 Metabolic Imaging; 1.4.3.5 Evaluation of Recurrence; References
2: Management of Non-muscle-Invasive and Muscle-Invasive Bladder Cancers2.1 Introduction; 2.2 Management of Non-muscle-Invasive Bladder Cancer; 2.3 Repeat/Restaging Transurethral Resection; 2.4 Intravesical Chemotherapy; 2.5 Intravesical Immunotherapy; 2.6 Treatment Alternatives During the Global Shortage of BCG; 2.6.1 Alternative BCG Schedules; 2.6.2 Alternative Intravesical Chemotherapy Applications; 2.7 Future Perspectives; 2.8 Treatment of Disease Unresponsive to or Relapsing After BCG Vaccination; 2.9 Upfront Cystectomy for Very High-Risk NMIBC
2.10 Surgical Management of Muscle-Invasive Bladder CancerReferences; 3: Target Volume Delineation Guidelines in Bladder Cancer; 3.1 Anatomy; 3.2 Role of Radiotherapy for Locoregional Disease; 3.3 Target Volume Delineation; 3.4 Definitive Radiotherapy for the Intact Bladder; 3.4.1 Gross Tumor Volume; 3.4.2 Clinical Target Volume; 3.4.3 Role of Elective Nodal Irradiation; 3.4.4 Planning Target Volume; 3.5 Adjuvant Setting; References; 4: Bladder Preservation Therapies in Bladder Cancer; 4.1 Introduction; 4.2 Management of Non-muscle-Invasive Bladder Cancer
4.3 Treatment of Muscle-Invasive Disease4.3.1 Monotherapy; 4.3.2 Multimodal Approach; 4.4 Metastatic Disease and Recurrences; 4.5 Irradiation Techniques; 4.5.1 Simulation, Target Volume, and Fields; 4.5.2 Tumor Localization; 4.5.3 Target Delineation; 4.5.4 Doses and RT Schedules; 4.5.5 IMRT and IGRT; 4.5.6 Brachytherapy; References; 5: Systemic Therapy for Bladder Cancer; 5.1 Introduction; 5.2 Systemic Therapies in Muscle-Invasive Bladder Cancer; 5.3 Treatment of Advanced and Metastatic Disease; 5.3.1 DNA-Targeted Chemotherapy; 5.3.2 Targeted Therapies; 5.3.3 Immunotherapy